Cancer immunotherapy has demonstrated impressive clinical benefits in fighting cancers by harnessing both innate and adaptive immune responses against tumor cells. CanWell is building its Immuno-oncology product platform through 2 anchoring programs, CAN1012, a TLR7 agonist, and DPV-001, a dendritic cell targeted cancer vaccine.